Drug
Programmed Cell Death 1 Receptor clinical trials
- studies test it
- 10
- open now
- 7
- in phase 3
- 3
- first study started
- 2017
Keep track of what changes. Save the Programmed Cell Death 1 Receptor studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2019 (4)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 4 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 2
- 7
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 8
Second Affiliated Hospital of Guangzhou Medical University (2) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Tianjin Medical University Cancer Institute and Hospital (1) · Sixth Affiliated Hospital, Sun Yat-sen University (1) · The Affiliated Hospital Of Guizhou Medical University (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · Tongji University (1) · Henlix, Inc (1)
Often tested with
Tested in the same studies.
Immune Checkpoint Inhibitors (2) · Antineoplastic Agents (1) · Programmed cell death 1 ligand 1 (1) · PD-L1 (1) · Apatinib (1)
Studies
Open first, then newest update. How each study uses Programmed Cell Death 1 Receptor is read from its arms, and is right about nine times in ten.
Testing it · 10
- Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct TumorsRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07726446Written as PD-1 and chemotherapy
- SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）RecruitingPhase 2Sixth Affiliated Hospital, Sun Yat-sen UniversityNCT06767007Written as PD1
- An Exploratory Study of Individualized Neo-antigen mRNA Cancer Vaccine InnoPCV in Advanced Solid Tumor TreatmentRecruitingEarly Phase 1The Affiliated Hospital Of Guizhou Medical UniversityNCT06497010Written as Biological: PD-1
- Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular CarcinomaRecruitingPhase 3Second Affiliated Hospital of Guangzhou Medical UniversityNCT03949231Written as PD1/PDL1 inhibitor
- IT or IA Infusion of PD1/PDL1/CTLA4 Inhibitors Versus IV for Immunotherapy of Head/Neck Cancers (HNC)RecruitingPhase 2/3Second Affiliated Hospital of Guangzhou Medical UniversityNCT03952065Written as PD1/PDL1/CTLA4 inhibitors
- Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)RecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06130332Written as PD-1 with chemotherapy
- A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver MutationsRecruitingPhase 3Tongji UniversityNCT05157776Written as PD-1 and chemotherapy
- Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's LymphomaCompletedPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT03114683Written as PD1
- Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B PatientsStatus unknownPhase 2Henlix, IncNCT04133259Written as Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibody
- Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric CancerStatus unknownPhase 2Henan Cancer HospitalNCT03954756Written as Apatinib and PD1